Aktuellt
SENASTE
Redeye notes a relatively uncontroversial Q3, with a continued stable cash position and funding until H2 2022. We are overall positive to the ongoing activities in the company and eagerly await the start of the phase IIb trial in PWS, next important catalyst in the company.
LÄS MER
